Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

0.7879
-0.0548-6.50%
Post-market: 0.7800-0.0079-1.00%19:56 EDT
Volume:924.50K
Turnover:733.66K
Market Cap:13.39M
PE:-0.34
High:0.8250
Open:0.8203
Low:0.7721
Close:0.8427
Loading ...

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

THOMSON REUTERS
·
19 Mar

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
14 Mar

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

ACCESS Newswire
·
11 Mar

BRIEF-Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement

Reuters
·
10 Mar

Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders’ Equity Requirement

THOMSON REUTERS
·
10 Mar

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

Insider Monkey
·
08 Mar

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Zacks
·
07 Mar

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
07 Mar

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
07 Mar

Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise

MT Newswires Live
·
07 Mar

Plus Therapeutics announces publication of results on 186Re Obisbemeda

TIPRANKS
·
07 Mar

US Stocks Likely To Open Higher After Nasdaq 100 Enters Correction Zone: 'Economic Resilience Provides A Foundation For Market Stabilization,' Says Expert

Benzinga
·
07 Mar

Equity Markets Drop as US Layoffs Surge, Tariff Tumult Persists

MT Newswires Live
·
07 Mar

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
07 Mar

Equity Markets Fall as US Layoffs Surge in February

MT Newswires Live
·
07 Mar

Top Midday Gainers

MT Newswires Live
·
07 Mar

Sector Update: Health Care Stocks Retreat Thursday Afternoon

MT Newswires Live
·
07 Mar

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge

MT Newswires Live
·
06 Mar

BRIEF-Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda

Reuters
·
06 Mar

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients With Lung Cancer

THOMSON REUTERS
·
06 Mar